Address correspondence to Dr Richard J. Barohn, Department of Neurology, Kansas University Medical Center, 3599 Rainbow Boulevard, Kansas City, KS 66160, email@example.com.
Relationship Disclosure: Dr Statland has served as a consultant for Cytokinetics, Inc, regarding outcome measures for facioscapulohumeral muscular dystrophy and receives salary support from the Muscular Dystrophy Association Clinical Research Training Grant. Dr Barohn has served on the speaker’s bureaus of Genzyme and Grifols; on the advisory boards of MedImmune, LLC, and Novartis Corporation; and as a consultant for NuFACTOR. Dr Barohn has received research support from Biogen Idec; BioMarin Pharmaceutical Inc; Cytokinetics, Inc; Genzyme Corporation; Knopp Neurosciences, Inc; Neuraltus Pharmaceuticals, Inc; the National Institute of Neurological Disorders and Stroke; the NIH; PTC Therapeutics; Sangamo BioSciences, Inc; Teva Pharmaceutical Industries Ltd; and the US Food and Drug Administration Office of Orphan Products Development.
Unlabeled Use of Products/Investigational Use Disclosure: Drs Statland and Barohn discuss the unlabeled use of carbonic anhydrase inhibitors for the treatment of hypokalemic periodic paralysis and mexiletine for the treatment of nondystrophic myotonia.
Supplemental digital content: Videos accompanying this article are cited in the text as Supplemental Digital Content. Videos may be accessed by clicking on links provided in the HTML, PDF, and iPad versions of this article; the URLs are provided in the print version. Video legends begin on page 1612.